US 12,390,551 B2
Compositions using iron excipients and their uses including for the treatment of cancer
Bryan S. Margulies, Liverpool, NY (US); and Nikhil A. Thakur, Andover, MA (US)
Assigned to Zetagen Therapeutics, Inc., Syracuse, NY (US)
Filed by Zetagen Therapeutics, Inc., Syracuse, NY (US)
Filed on Sep. 6, 2023, as Appl. No. 18/462,292.
Application 18/462,292 is a continuation of application No. 17/143,468, filed on Jan. 7, 2021.
Claims priority of provisional application 63/053,277, filed on Jul. 17, 2020.
Prior Publication US 2024/0016976 A1, Jan. 18, 2024
Int. Cl. A61L 27/12 (2006.01); A61K 31/485 (2006.01); A61L 27/04 (2006.01); A61L 27/24 (2006.01); A61L 27/54 (2006.01)
CPC A61L 27/12 (2013.01) [A61K 31/485 (2013.01); A61L 27/042 (2013.01); A61L 27/24 (2013.01); A61L 27/54 (2013.01); A61K 2300/00 (2013.01); A61L 2300/204 (2013.01); A61L 2300/602 (2013.01); A61L 2300/802 (2013.01); A61L 2430/02 (2013.01); A61L 2430/38 (2013.01)] 13 Claims
OG exemplary drawing
 
1. A method of treating a patient having a cancer selected from the group consisting of lung cancer, breast cancer and prostate cancer, comprising identifying a bone defect in the patient caused by the cancer or resulting from treatment of the cancer, locally administering at the site of the bone defect in the cancer patient in need thereof a composition consisting of a calcium phosphate, an OGFR antagonist, an iron excipient, an optional curing agent, and at least one of the following: an acidifying agent, collagen, and a diluent saline solution, wherein the composition provides a therapeutically effective amount of the iron excipient that increases mineral formation at the site of the bone defect, and wherein the iron excipient is iron (III) sulphate.